Sagent Pharmaceuticals and Qilu Pharmaceutical Co. announced a strategic collaboration to commercialize a portfolio of complex injectable products for the US market.
Through this partnership, Sagent will have exclusive rights to commercialize a select portfolio of Qilu's complex injectable products in the U.S. These products span high-impact therapeutic areas and represent a significant opportunity to address unmet patient needs across the U.S. healthcare landscape.
The combined total addressable market for these products is estimated to exceed $4.5 billion, reflecting strong demand across Sagent's key therapeutic areas. The collaboration aims to enhance access, reduce treatment costs, and strengthen supply resilience for these critical medications.
"This collaboration represents a key milestone in our strategy to build a robust and differentiated U.S. pharmaceutical portfolio," said Dr. Vishy Chebrol, CEO of Sagent. "We are excited to partner with Qilu to bring high-value, clinically essential therapies to market and ensure they reach the patients who need them most."
"We are pleased to collaborate with Sagent to expand the availability of Qilu's high quality, complex injectable products in the U.S. market," said Hanchang Zhang, Vice President of Qilu-Pharma Group. "This collaboration reflects Qilu's commitment to delivering safe, effective, and affordable medicines to patients worldwide. By combining Qilu's proven development and manufacturing capabilities with Sagent's strong commercial platform, deep market insight, and agile market approach, we look forward to advancing patient care and contributing to a more reliable, accessible pharmaceutical supply chain."
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!